(Q36150511)

12 August 2017

1 reference

title

Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer (English)

1 reference

12 August 2017

1 reference

Jun Yan

1

1 reference

12 August 2017

Daniel J Allendorf

series ordinal

2

1 reference

12 August 2017

Brian Brandley

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Expert Opinion on Biological Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

5

1 reference

12 August 2017

page(s)

691-702

1 reference

Cancer immunotherapy: breaking the barriers to harvest the crop

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Natural history of HLA expression during tumour development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Trastuzumab: hopes and realities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Complement function in mAb-mediated cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Targeting of radio-isotopes for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Comparative tumor-inhibitory and anti-bacterial activity of soluble and particulate glucan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Development, physicochemical characterization and preclinical efficacy evaluation of a water soluble glucan sulfate derived from Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

NMR spectral analysis of a water-insoluble (1-->3)-beta-D-glucan isolated from Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

The ultrastructure of yeast: cell wall structure and formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

A method for the solubilization of a (1→3)-β-d-glucan isolated from Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficacy in rats infected with antibiotic-resistant bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

CD55 is over-expressed in the tumour environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Dectin-1 mediates the biological effects of beta-glucans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

The beta-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Natural killer lymphocytes: biology, development, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Characterization of synthetic C3a analog peptides on human eosinophils in comparison to the native complement component C3a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Complement factors and their receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Immunotherapy of malignant diseases. Challenges and strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Therapeutic intervention with complement and beta-glucan in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Robust ability of IFN-gamma to upregulate class II MHC antigen expression in tumor bearing rat brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Immune system versus tumor: shifting the balance in favor of DCs and effective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Function and regulation of chemoattractant receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

Clinical Evaluation of Sizofilan as Assistant Immunotherapy in Treatment of Head and Neck Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.5.691

21 January 2018

Identifiers

DOI

10.1517/14712598.5.5.691

1 reference

12 August 2017

1 reference